BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2019

Feb 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2019-01-31

Reporting Person: Babu Yarlagadda S (Senior VP - Drug Discovery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-31	Common Stock	M	19686	$1.20	Acquired	127786	Direct
2019-01-31	Common Stock	F	7702	$8.68	Disposed	120084	Direct
2019-01-31	Common Stock	M	12188	$1.20	Acquired	132272	Direct
2019-01-31	Common Stock	F	1685	$8.68	Disposed	130587	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-31	Non-Qualified Stock Option	$1.20	M	19686	Disposed	2019-03-02	Common Stock (19686)	Direct
2019-01-31	Emp. Stock Option (Right to Buy)	$1.20	M	12188	Disposed	2019-03-02	Common Stock (12188)	Direct

Footnotes

F1: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.

F2: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.